Prana candidate reduces Abeta levels
Thursday, 10 July, 2008
Key findings from Prana Biotechnology's [ASX: PBT] preclinical research of its proprietary PBT2 Alzheimer's drug have been published in the prestigious scientific journal Neuron.
The article, "Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxyquinoline analogs is associated with decreased interstitial Abeta," can be viewed on-line by Neuron subscribers.
PBT2 was found to rapidly and profoundly improve cognition in transgenic mice, by substantially reducing the amount of Abeta - amyloid beta, the main constituent of Alzheimer's plaques - in the brain over a nine-month period.
The findings will be presented at the 11th International Conference on Alzheimer's Disease, to be held in Chicago at the end of the month.
Low-dose drug prevents diabetes progression in young people
A low dose of the immunomodulatory drug anti-thymocyte globulin (ATG) appears safe and effective...
Mediterranean-style diet benefits maternal and infant health
Two studies have found that a Mediterranean-style diet benefits maternal health during pregnancy...
Genes play an active role in gut health, researchers find
It appears that genes play an active role in shaping bacterial communities, putting into question...
